

Supplementary**Table S1** Collocation selection of systemic combination therapy at baseline

Variable	TACE group (n=98), n (%)		Non-TACE group (n=49), n (%)	
	Sorafenib	Lenvatinib	Sorafenib	Lenvatinib
Nivolumab	14 (14.3)	7 (7.1)	5 (10.2)	1 (2.0)
Pembrolizumab	4 (4.1)	14 (14.3)	2 (4.1)	4 (8.2)
Camrelizumab	40 (40.8)	19 (19.4)	30 (61.2)	7 (14.3)

Except where indicated, data are numbers of patients, with percentages in parentheses.